ArticleCancer management and research2019
Undifferentiated Pleomorphic Sarcoma: Long-Term Follow-Up from a Large Institution.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Management of intracranial undifferentiated pleomorphic sarcoma: a systematic review.Neurosurgical review · 2026Pooled it
- Pleomorphism in Soft Tissue Sarcomas: Molecular Characteristics and Clinical Features.Medical sciences (Basel, Switzerland) · 2026Review
- Misdiagnosed undifferentiated pleomorphic sarcoma of the right lower leg mimicking atypical fibroxanthoma: a case report and literature review.Frontiers in oncology · 2026Article
- Case Report: A rare case of primary undifferentiated pleomorphic sarcoma of the renal pelvis with high PD-L1 expression and a misleading positive urine FISH.Frontiers in immunology · 2026Article
- ASO Author Reflections: Advancing Prognostics in Oncology: Developing a Machine Learning Model for Predicting 2-Year and 5-Year Survival Rates in Patients with Undifferentiated Pleomorphic Sarcoma.Annals of surgical oncology · 2026Article
- Undifferentiated High-Grade Pleomorphic Sarcoma of the Posterior Mandible: A Report of a Rare Case.Cureus · 2026Article
- A rare incidence of primary pulmonary undifferentiated pleomorphic sarcoma detected as an endobronchial mass and treated by bronchoscopic resection: a case report and literature review.Frontiers in oncology · 2026Article
- Clinicopathological and genomic profiling in undifferentiated pleomorphic sarcoma: Small series, clear message.Journal of applied genetics · 2025Article
- Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcoma.Molecular oncology · 2025Article
- Is the Thickness of the Margin Associated with Local Recurrence and Survival in Patients with Undifferentiated Pleomorphic Sarcoma?Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Advancing Prognostics in Oncology: Developing a Machine Learning Model for Predicting 2-Year and 5-Year Survival Rates in Patients with Undifferentiated Pleomorphic Sarcoma.Annals of surgical oncology · 2025Article
- Article
- Article
- Large retroperitoneal mass: A case of an undifferentiated pleomorphic sarcoma.Radiology case reports · 2025Article
- Article
- Undifferentiated Pleomorphic Sarcoma of Laryngeal Ventricle: A Case Report.Oman medical journal · 2025Article
- Two Cases of Intraocular Undifferentiated Pleomorphic Sarcoma.Ocular oncology and pathology · 2024Article
- Decoding Chemotherapy Resistance of Undifferentiated Pleomorphic Sarcoma at the Single Cell Resolution: A Case Report.Journal of clinical medicine · 2024Article
- Undifferentiated Pleomorphic Sarcoma with Reactive Eccrine Syringofibroadenoma: A Case Report.Dermatopathology (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOur study aimed to describe the clinical features of undifferentiated pleomorphic sarcoma (UPS) and identify the predictors of poor outcomes. PATIENTS AND
methodsThe clinicopathological variables and treatment strategies of 100 UPS patients who underwent surgical resections at a single institution between November 2004 and July 2016 were reviewed. Kaplan-Meier and Cox regression method were conducted for survival analysis.
resultsThe median follow-up time was 94 months (range, 1.5-154 months). R0 resection was applied for 72 cases, and the median tumor size was 5.75cm (range, 1-30cm). Tumor grades of 45 patients were intermediate grade (G2), and 54 patients were with advanced stage (stage III/IV). Twenty-seven patients presented with tumors involving important structures, in which the nerve was the most frequently invaded structure (n=12). During the follow-up, 40 patients suffered from postoperative local recurrence, and distant metastasis was observed in 25 patients which mainly metastasized to the lung (n=14). The 5-year OS rate, 5-year LRFS rate, and 5-year MFS rate was 53%, 55%, and 70%, respectively. Multivariate analysis revealed that tumor presentation, tumor size, and important structures involved (p=0.033, p=0.004, and p=0.033, respectively) were independent prognostic factors associated with OS. Meanwhile, age, resection quality and tumor grade were independent prognostic factors for LRFS (p=0.033, p=0.045, and p=0.007, respectively) and tumor depth was significantly associated with MFS (p=0.050) in multivariate analysis.
conclusionPrimary treatment of UPS should be conducted by experts in large sarcoma center. Wide surgical margin provides sufficient control of the disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.